Best known as the “women’s” hormone. Has many roles but is primarily responsible for the growth and maintenance of the female reproductive system and sexual characteristics. Estrogen is produced in the ovaries, adrenal glands and in fat and it is then distributed to the body via the blood stream.
When we start to lose estrogen whether it is from menopause or menopause induced by a hysterectomy many changes take place and estrogen replacement a.k.a. Hormone Replacement Therapy (HRT) is very important. The goal of Estrogen HRT should be to achieve the lowest dose that reverses a woman’s symptoms.
Is estrogen dangerous or bad for me?
In 2002 the Women’s Health Initiative (WHI) did a study on long term estrogen and progestin. The findings showed that the health risks of HRT outweighed the benefits and there were increased risk of breast cancer and heart disease. This study researched oral conjugated equine estrogen Premarin and only medroxyprogesterone acetate Prempro as the hormone replacement and these did show an increase in breast cancer, coronary heart disease, stroke and pulmonary embolism.
This study did not take into effect the bio-identical hormones that are now available and found to be much safer than the equine estrogen that was used.
In 2017 the North American Menopause Society (www.menopause.org) reviewed the data and released a position statement indicating the safety of HRT.
The 2017 hormone therapy position state of The North American Menopause Society.
(Menopause: The Journal of The North American Menopause Society Vol. 24, No 7, pp 728-753)
Hormone Therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (FSM and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, and duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT.
For Women younger than 60 years or who are within 10 years of menopause and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at high risk for bone loss or fracture. For women who initiate HT more than 10 or 20 years from menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. For bothersome GSM symptoms not relieved with over-the-counter therapies and without indications for use of systemic HT, low-dose vaginal estrogen therapy or other therapies are recommended.